University of Hawaii Cancer Center, Honolulu, HI, USA.
Am J Surg. 2012 Jun;203(6):726-32. doi: 10.1016/j.amjsurg.2011.06.055. Epub 2012 Jan 9.
Hawaii has the highest incidence of hepatocellular cancer (HCC) in the United States and the largest proportion of Asians and Pacific Islanders. HCC studies generally combine these groups into 1 ethnicity, and we sought to examine differences between Asian and Pacific Islander subpopulations.
Demographic, clinical, and treatment data for 617 patients with HCC (420 Asians, 114 whites, and 83 Pacific Islanders) were reviewed. Main outcome measures included HCC screening and liver transplantation.
Asian and Pacific Islander subgroups had significantly more immigrants, and age was different between groups. Compared with whites, Pacific Islanders and Filipinos had less HCC screening and liver transplantation procedures, fewer met Milan criteria, and a smaller proportion of those with Milan criteria actually underwent transplantation.
There were significant differences in risk factors, clinical presentation, treatment, and access to care among Asian, Pacific Islander, and white patients with HCC. Future HCC studies may benefit from differentiating subgroups within Asian and Pacific Islander populations to better focus these efforts.
夏威夷是美国肝细胞癌（HCC）发病率最高的地区，也是亚洲人和太平洋岛民比例最大的地区。HCC 研究通常将这些人群合并为 1 个种族，我们试图研究亚洲和太平洋岛民亚群之间的差异。
回顾了 617 例 HCC 患者（420 名亚洲人、114 名白人、83 名太平洋岛民）的人口统计学、临床和治疗数据。主要观察指标包括 HCC 筛查和肝移植。
亚洲和太平洋岛民亚组的移民人数明显更多，且各组之间的年龄存在差异。与白人相比，太平洋岛民和菲律宾人 HCC 筛查和肝移植的比例较低，符合米兰标准的患者较少，符合米兰标准的患者中实际接受移植的比例也较小。
亚洲、太平洋岛民和白人 HCC 患者在危险因素、临床表现、治疗和获得治疗方面存在显著差异。未来的 HCC 研究可能会受益于区分亚洲和太平洋岛民人群中的亚组，以便更好地集中精力。
